Tips and tricks in endoscopic papillectomy of ampullary tumors: single-center experience with large case series (with videos)

2015 ◽  
Vol 22 (6) ◽  
pp. E22-E27 ◽  
Author(s):  
Shujiro Tsuji ◽  
Takao Itoi ◽  
Atsushi Sofuni ◽  
Shuntaro Mukai ◽  
Ryosuke Tonozuka ◽  
...  
2017 ◽  
Vol 152 (5) ◽  
pp. S883-S884
Author(s):  
Danielle La Selva ◽  
Richard A. Kozarek ◽  
Russell Dorer ◽  
Michael Gluck

2021 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Takao Itoi ◽  
Yukitoshi Matsunami ◽  
Atsushi Sofuni ◽  
Takayoshi Tsuchiya ◽  
Kentaro Ishii ◽  
...  

2020 ◽  
Vol 34 (8) ◽  
pp. 840-846
Author(s):  
Ibraheem Alrishan Alzouebi ◽  
Aled Williams ◽  
Nambi Rajan Thiagarjan ◽  
Manal Kumar

2021 ◽  
pp. 10.1212/CPJ.0000000000001078
Author(s):  
Yasmin Aghajan ◽  
Alison Yu ◽  
Caron A. Jacobson ◽  
Austin I. Kim ◽  
Leslie Kean ◽  
...  

Chimeric antigen receptor T (CART) cell therapy is highly effective for relapsed/refractory hematologic malignancy [1,2]; however, cytokine release syndrome (CRS) and neurotoxicity are observed in up to 77% of patients [3]. In large case series, the most common presentations of neurotoxicity were encephalopathy (57%), headache (42%), tremor (38%) and aphasia (35%). CART mediated spinal cord toxicity is not well characterized. Structural neurologic damage (stroke and intracranial hemorrhage) was only observed in 1-2% and seizures were seen in 1%-8% of cases [3, 4]. Neuroimaging findings in patients with neurotoxicity are rare and not specific.


2020 ◽  
Vol 95 (3) ◽  
pp. 181-187
Author(s):  
Han Hee Lee ◽  
Young-Seok Cho

Fecal microbiota transplantation (FMT), which has been established as the standard treatment for recurrent <i>Clostroides</i> difficile infection, may also play a role in the management of other diseases associated with dysbiosis of the gut microbiota. To ensure efficacy and safety of FMT, an appropriate donor screening process is required. The main purpose of donor screening is to check for infectious diseases that could be transmitted to the recipient. The screening process involves a medical history questionnaire, and blood and stool testing. Several randomized clinical trials and large case series on FMT reported no, or few, adverse events related to infection by following this donor screening process. However, there is still concern over the transmission of antibiotic-resistant bacteria. In addition, a low donor acceptance rate due to rigorous screening makes donor recruitment difficult, and also imposes a significant cost burden. A consensus on the most crucial elements of donor screening is needed for wide application of FMT.


Sign in / Sign up

Export Citation Format

Share Document